Business Wire

REPLY

12.2.2024 09:31:34 CET | Business Wire | Press release

Share
REPLY: Concept Reply's Test Automation Framework Innovates the Monitoring of Electric Vehicle (EV) Charging Stations Through Artificial Intelligence and Machine Learning

Concept Reply, a company within the Reply Group specialising in IoT innovation, has expanded the capabilities of its Test Automation Framework to include the validation of electric vehicle charging systems. Using digital models (digital twins) integrated into the proprietary test cycle automation framework, Concept Reply's solution allows for the measurement of reliability, efficiency, and safety levels of charging stations by simulating complex scenarios in a controlled virtual environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212429452/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Reply's Global Test Automation Center is reshaping the landscape of EV charging testing with its end-to-end Test Automation Framework. Implemented at the Global Test Automation Center, Reply's laboratory specialising in the automation of product and service tests, the new Test Automation Framework for charging systems provides 360-degree monitoring of all touchpoints connected to the charging station. (Photo: Business Wire)

Implemented at the Global Test Automation Center, Reply's laboratory specialising in the automation of product and service tests, the new Test Automation Framework for charging systems provides 360-degree monitoring of all touchpoints connected to the charging station. This includes web portals, mobile applications, charging stations, and electric vehicle simulators. With the integration of artificial intelligence and machine learning, the framework not only implements standard end-to-end testing functions but also includes specific scenarios to verify interactions between various components and devices in a complex outdoor ecosystem managed by multiple entities.

The progressive transformation of the transport ecosystem towards smart mobility models and V2X scenarios is leading to a rapid increase in installed charging stations. This necessitates operators of sustainable mobility to provide services that are not only user-friendly but increasingly reliable and secure. In this scenario, digital competencies are crucial for managing both charging infrastructures and vehicles.

Reply supports companies involved in the entire new mobility supply chain by developing new application architectures to support the development of infrastructure and charging processes. This includes the creation of innovative systems enabling new models of energy flexibility, such as vehicle-to-home, vehicle-to-grid, microgrid, and energy community management.

Concept Reply's framework is designed to enable automakers, electric utility operators, and stakeholders to rigorously verify the compatibility of charging devices, both public and private, with various EV models and communication protocols. Through tests that assess performance on multiple levels, such as power, vehicle types, and environmental factors, the framework ensures continuity in interactions between vehicles and charging stations, ensuring quality services and reliability in the products offered.

To learn more about Test Automation Framework for Charging System Validation and Reply's quality engineering expertise, visit www.reply.com/en/quality-engineering.

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

Concept Reply
Concept Reply specializes in the research, development, and validation of innovative solutions in the IoT (Internet of Things) field. Today, we are recognized as a center of expertise and excellence in Testing and Quality Assurance, and include a Business Unit that specializes in this service. Thanks to our laboratories and to an international team of professionals specializing in the QA and Validation fields, we are able to offer companies end-to-end support for the validation of products and services, while also optimizing costs and time-to-market. www.concept.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212429452/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye